Adcon market return?
This article was originally published in The Gray Sheet
Executive Summary
Wright Medical's potential re-launch of Gliatech's anti-adhesion gel, following purchase of the product line from the bankrupt Cleveland biosurgery firm Jan. 3, is welcomed by Genzyme Biosurgery President Duke Collier. In an April 16 earnings call, Collier notes: "Our product [Sepra] is not used in the spine...so I don't think there will be much effect" from an Adcon re-launch. "We're happy that we've got an unambiguously safe and unambiguously effective product out there, [but] to be honest, it would not be the worst thing to have another one...I kind of wish Wright luck with this"...